Completed PHASE2 INTERVENTIONAL NCT00312273

Aminophylline in Bradyasystolic Cardiac Arrest

Aminophylline in Bradyasystolic Cardiac Arrest: A Randomized Placebo-Controlled Trial

Sponsor: Heart and Stroke Foundation of Canada

Interventions Aminophylline (250mg IV +/- a second dose of 250mg IV)

Updated 5 times since 2017 Last updated: Jul 26, 2006 Started: Jan 31, 2001 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cardiac Arrest and is currently completed. Heart and Stroke Foundation of Canada leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Heart and Stroke Foundation of Canada
Vancouver Coastal Health Research Institute
Vancouver General Hospital

Data source: Vancouver General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vancouver, Canada